James P. Brady
Human Resources Officer chez SPERO THERAPEUTICS, INC.
Profil
James P.
Brady is currently the Chief Human Resource Officer at Spero Therapeutics, Inc. Previously, he held the position of Vice President-Human Resources at Intarcia Therapeutics, Inc. and was the Chief Human Resources Officer at uniQure NV.
He received a graduate degree from Harvard University and an undergraduate degree from Marietta College.
Postes actifs de James P. Brady
Sociétés | Poste | Début |
---|---|---|
SPERO THERAPEUTICS, INC. | Human Resources Officer | - |
Anciens postes connus de James P. Brady
Sociétés | Poste | Fin |
---|---|---|
UNIQURE N.V. | Human Resources Officer | - |
Intarcia Therapeutics, Inc.
Intarcia Therapeutics, Inc. BiotechnologyHealth Technology Intarcia Therapeutics, Inc. develops therapies for the treatment of chronic diseases. Its lead product candidate, ITCA 650, is currently in development for the treatment of type 2 diabetes. The firm’s platform technology is a proprietary subcutaneous delivery system that involves a matchstick-size, miniature osmotic pump implanted sub-dermally to provide continuous and consistent drug therapy, and the company’s proprietary formulation technology, which maintains stability of therapeutic proteins and peptides at human body temperatures for long extended periods of time. The company was founded by Mark Moran in June 1995 and is headquartered in Boston, MA. | Human Resources Officer | - |
Formation de James P. Brady
Harvard University | Graduate Degree |
Marietta College | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
Sociétés cotées | 2 |
---|---|
UNIQURE N.V. | Health Technology |
SPERO THERAPEUTICS, INC. | Health Technology |
Entreprise privées | 1 |
---|---|
Intarcia Therapeutics, Inc.
Intarcia Therapeutics, Inc. BiotechnologyHealth Technology Intarcia Therapeutics, Inc. develops therapies for the treatment of chronic diseases. Its lead product candidate, ITCA 650, is currently in development for the treatment of type 2 diabetes. The firm’s platform technology is a proprietary subcutaneous delivery system that involves a matchstick-size, miniature osmotic pump implanted sub-dermally to provide continuous and consistent drug therapy, and the company’s proprietary formulation technology, which maintains stability of therapeutic proteins and peptides at human body temperatures for long extended periods of time. The company was founded by Mark Moran in June 1995 and is headquartered in Boston, MA. | Health Technology |